Northwest Therapies Trauma Psilocybin Study Compassionate Use Study

This Phase I intervention trial (n=30) conducted by Northwest Therapies Trauma Psilocybin Study (NWTTPS) aims to assess the efficacy and safety of enhanced microdosing of psilocybin in treating chronic illnesses such as Trauma, PTSD, Chronic Depression, MS, HIV, and SARS-CoV-2 Long Haulers Syndrome.

The trial utilises non-synthesized psilocybin, administered at enhanced microdose levels (ranging from 0.15g to 0.33g) every other day for 5 days, followed by a maintenance dose of 1 gram to 1.5 grams monthly for 8 weeks. The study hypothesises that psilocybin microdosing could help alleviate symptoms associated with these chronic conditions by rerouting neural pathways and reducing ruminating neurotransmitters.

Patients will work closely with a team including a Psychiatrist, LCPC Therapist, and a Plant Medicine On-Boarding Provider.

The primary outcome measures include the Global Assessment of Functioning (GAF) score and the Brief Addiction Monitor (BAM) score, assessed monthly by the team. Secondary outcome measures include the Posttraumatic Stress Disorder Checklist-5 (PCL-5) score.

The study is set to commence in September 2023 and is estimated to be completed by October 2025.

Topic PTSD Depression
Compound Psilocybin
Country United States of America
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

NWTraumatherapies


Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.